BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

BSP - Biological Signal Processing Ltd. Receives FDA Approval For New ECG Technology


10/19/2005 5:13:09 PM

TEL-AVIV, Israel, March 29 /PRNewswire/ -- BSP Biological Signal Processing Ltd. announces that it has received FDA approval for the marketing and sale of its HyperQ(TM) System.

BSP, a world pioneer in the field of high-frequency ECG (HF ECG), has developed superior ECG technology, with breakthrough diagnostic value for detecting and monitoring ischemic heart diseases (IHD) - the leading cause of death in the developed world.

BSP's HyperQ(TM) System is a unique PC-based stress ECG device, that records, analyses and displays both conventional stress ECG and HF ECG for detection of myocardial ischemia.

The system uses BSP's proprietary signal acquisition and signal processing technology and offers user-friendly interface, numerical readout of the results, as well as self-explanatory graphs, to demonstrate changes in the high frequency components of the QRS complex.

BSP has recently concluded a successful large-scale, 1000-patients study, currently in writing for publication.

"Studies in animals and humans demonstrated a distinct pattern of decrease in the High Frequency QRS (HF QRS) components during acute myocardial ischemia", says Dr. Irit Yaniv, BSP's VP Clinical and Business Development, "Moreover, reperfusion yielded the opposite pattern, suggesting that the HyperQ(TM) technology offers a great potential in detecting ischemic conditions and reperfusion success with unmatched accuracy".

"BSP's first FDA approval is an exciting and essential milestone in the road to global recognition of our technology", says Dr. Amir Beker, BSP's CEO and

Founder, "together with the already received European ISO and CE certificates, it enables the introduction of our products to the US and European markets"

BSP's next products include rest and monitoring systems, telemedicine devices and application for implantable cardiac devices (ICDs).

BSP was founded in 2000, and its team consists of top signal processing experts, biomedical engineers and clinicians. BSP's chief scientist is Prof. Shimon Abboud - a pioneering researcher of HF ECG for more than 25 years, and world leader in the field.

For more information: please visit us at http://www.bsp.co.il/ or contact Amir Beker, CEO - amir@bsp.co.il Irit Yaniv, VP Clinical and Bus. Dev. - irit@bsp.co.il Tel. +972-3-6474840

BSP - Biological Signal Processing Ltd

CONTACT: For more information: please visit us at http://www.bsp.co.il/ orcontact Amir Beker, CEO - amir@bsp.co.il; Irit Yaniv, VPClinical and Bus. Dev. - irit@bsp.co.il, Tel. +972-3-6474840


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->